Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens
Name
2023_Adv Healthcare Materials_Karavasili - Modular Titratable Polypills for Personalized Medicine and Simplification.pdf
Description
Published version
Size
1.78 MB
Format
Adobe PDF
Checksum (MD5)
ae74137284c5698f6b4dbd7b02a97512
Author(s)
Karavasili, Christina
Babaee, Sahab
Kutty, Shruti
Chu, Jacqueline N.
Min, Seokkee
Fitzgerald, Nina
Morimoto, Joshua
Inverardi, Nicoletta
Traverso, Giovanni
Date Issued
August 13, 2023
Journal
Advanced Healthcare Materials
Publisher
Wiley
Citation
C. Karavasili, S. Babaee, S. Kutty, J. N. Chu, S. Min, N. Fitzgerald, J. Morimoto, N. Inverardi, G. Traverso, Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens. Adv. Healthcare Mater. 2023, 12, 2301101.
Version
Final published version
Abstract
Simplification of complex medication regimens in polypharmacy positively contributes to treatment adherence and cost‐effective improved health outcomes. Even though fixed dose combination (FDC) drug products are the only currently available single dose poly‐pill regimens, the lack of flexibility in dose adjustment of a single drug in the combination limits their efficacy. To fill the existing gap in drug dose personalization and simplification of complex medication regimens commonly encountered in the treatment of cardiovascular disease, tuberculosis, and tapering of corticosteroid therapy, a modular titratable polypill approach that simultaneously addresses both aspects is proposed. The polypill consists of modular units that contain different drugs at incremental or decremental doses to be assembled in a single titratable polypill at the required dose for each drug through a stacking or interlocking process. The variable dose (VD) modular tablets are subjected to quality control tests and found to comply to pharmacopeia's acceptance criteria and requirements specified in the respective drug monographs. A cost‐effectiveness analysis is conducted supporting the VD strategy as cost‐effective compared to the FDC strategy and more effective and less expensive than standard of care. The VD approach stands to enable pill burden reduction, ease of administration, enhancement of treatment adherence, and potential cost‐saving benefits.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
10.1002/adhm.202301101
